SWITCH Biotech - Specializing in Dermatology



SWITCHBIOTECH's mission is to capitalize on the current and emerging market opportunities in dermatology drug development.

Business Model

The company's major strength is the identification and validation of drug candidates. Our comprehensive knowledge of the molecular biology of the skin is a powerful and sustainable resource for the identification of novel drugs. SWITCHBIOTECH has identified no less than five compounds that exhibit attractive biological activities for potential dermatologic treatments and other therapeutic conditions.

About Us

SWITCHBIOTECH is a privately held biotech company specializing in the research and development of prescription dermatology products.


Dermatology Market

The global dermatology market exceeds $18 billion.  In the U.S. the market is $5.9 billion and in Europe a total of $5.7 billion.  It has grown an average of nearly 7% yearly since 2001.  There is a wide disparity between these sales figures and current drug development activities: Only 1-2% of all development activities are for dermatological conditions. Furthermore, current pipeline activity is mainly limited to psoriasis and anti-infectives.

Despite large patient populations with significant unmet needs, comparatively few new dermatology products have come to market in recent years. The important drug classes currently used in dermatology, such as steroids and retinoids, generally represent old products that have been on the market for a long time. Generics dominate the market, and many important branded products will lose patent protection in the near term. This lack of innovation has resulted in sales growth below the industry average of 9%.

SWITCHBIOTECH is currently in the early stages of research and development of several products that it may potentially submit to the FDA for regulatory approval. Our therapeutic efforts are focused on therapies for Psoriasis, Acne Vulgaris, Actinic Keratoses, Atopic Dermatitis, Cutaneous Ulcers and Onychomycosis (nail fungus).  Additionally we are investigating other compounds for the treatment of conditions outside of dermatology.

We are investigating traditional pharmaceutical compounds and biotechnology approaches to treat diseases of the skin. Our R&D efforts are derived from in-house sources and potential licensing agreements with research and development partners worldwide.